Navigation Links
Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
Date:9/19/2011

ood and Drug Administration and to submitting a Marketing Authorization Application to the European Medicines Agency thereafter.  We also are advancing our ongoing Phase Il trial in osteoporosis prevention, an indication for which our oral calcitonin could be especially relevant."

Tarsa's oral calcitonin is also being assessed in a double-blind Phase II study comparing the OSTORA tablet to placebo in postmenopausal women who have low bone mass (osteopenia) and are at increased risk of fracture.  This proof-of-concept study is evaluating the ability of oral calcitonin to prevent osteoporosis and maintain bone mass in this population.  

Tarsa is developing its OSTORA oral calcitonin under a licensing agreement with Unigene Laboratories that provides Tarsa with exclusive development and worldwide commercialization rights to Unigene's oral calcitonin product, with the exception of China.  For more information on Unigene, see www.unigene.com.

The American Society for Bone and Mineral Research 2011 Annual Meeting, the premier scientific meeting discussing the latest concepts and innovations in bone and mineral research, is being held September 16-20, 2011 in San Diego, California.  For more information, visit www.asbmr.org/Meetings/AnnualMeeting.aspx .

"Results of the ORACAL Trial: A Phase 3 Randomized Trial of the Safety and Efficacy of Orally Administered Recombinant Salmon Calcitonin Tablets in Postmenopausal Women with Osteoporosis," Neil Binkley MD, Michael Bolognese MD, James P Gilligan PhD, David S Krause MD.  Presented at the ASBMR 2011 Annual Meeting, Oral Session 23, 2:30pm PDT, September 18, 2011.

*The International Osteoporosis Foundation. Osteoporosis: The Inside Story. Fact sheet. Retrieved August 29, 2011, from

SOURCE Tarsa Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
2. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
3. Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
4. Echo Therapeutics Receives Registered Trademarks for Symphony® and Prelude®
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
6. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
7. Rare Disease Therapeutics, Inc. Selects Accredo Health Group to Distribute Anascorp® for the Treatment of Centruroides Scorpion Sting Envenomation
8. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
9. Nile Therapeutics to Present at Rodman & Renshaw Global Investment Conference
10. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
11. Global Sepsis Therapeutics Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "China Orthopedic Instrument Industry Report, 2014-2017" report to ... population and rising proportion of reimbursement for medical expenses, ... released, with its scale presenting a CAGR of 19.2% ... are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... CB1,antagonist rimonabant to show benefits beyond weight reduction ... | March 08, 2007 | The Business Intelligence,firm ... antagonist Acomplia (rimonabant) has at least,five competitors in ... more,in earlier phases of R&D. While Acomplia received ...
... March, 9, 2007-Active Biotech (ACTI.ST), today,announced new positive clinical ... treatment of prostate cancer. , By step-wise dose escalation, ... which corresponds to a doubling of the previously,reported maximum ... a step-wise intra-patient dose-escalation enables a dose,of 1 mg/day ...
Cached Medicine Technology:Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 2Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 3Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer 2
(Date:8/31/2014)... Sunday 31 August 2014: Mortality and morbidity ... year despite good use of oral anticoagulants, according to ... General Pilot Registry. The findings were presented for the ... chairperson Professor Gregory Lip (Birmingham, UK). , Professor Lip ... focused on management practices of European cardiologists conducted since ...
(Date:8/30/2014)... Sunday 31 August 2014: A new batteryless cardiac ... by heart motion was presented at ESC Congress ... prototype device does not require battery replacement. , ... Engineering Group at ARTORG, University of Bern, Switzerland, ... medical implants. Once they reach a critically low ...
(Date:8/30/2014)... In a world where a typical response to conflict ... launches a game app to teach another way. Launched ... app is a colorful way to encourage moral values playfully. ... pulls double-duty by teaching players new ways to find happiness ... gamers for consistently taking the high road, the Ultimate Karma ...
(Date:8/30/2014)... August 31, 2014 Atlanta based automotive ... to help raise money and awareness for ALS by ... General Managers, staff, and even Vice President Jimmy Ellis ... film and can be viewed on their Youtube page; ... the challenge, general managers and staff also took the ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 The ... modeling the body that will reveal to users some shocking ... lead to great results in modeling looks, as well as ... the new method says that there is one unique trick ... new method indicates that despite what many people might think, ...
Breaking Medicine News(10 mins):Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:Newly Launched Ultimate Karma App Elicits Happiness in Players and Encourages Moral Values 2Health News:Jim Ellis Automotive Group Take the ALS Ice Bucket Challenge 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2
... 30 Physicians Healthcare,Management Group, Inc. (Phyhealth) (Pink Sheets: ... with physicians,today announced that its board of directors has ... of the Company,s outstanding Common Stock., The shares ... market price.,The purchases will be made at the Company,s ...
... (Logo: http://www.newscom.com/cgi-bin/prnh/20050825/CLTH069LOGO ), What: HCA ... 2008 @ 9:00 am CT, Where: http://www.videonewswire.com/event.asp?id=52343 , ... log on to the web at the ... HCA Healthcare, 615-344-2688, ...
... /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ("China Sky ... ), a,leading fully integrated pharmaceutical company producing over-the-counter,drugs ... today that it,recently obtained production approval from the ... two of its newly developed drugs., Sodium ...
... ANGELES, Oct. 30 Cardo Medical, a company ... the FDA 510k,clearance of its Align 360 Total ... planned for commercial release during the second quarter ... the flagship product within,its Align 360 platform which ...
... at 1:30 p.m. (Pacific); ... http://www.adventrx.com , SAN DIEGO, Oct. 30 ADVENTRX Pharmaceuticals,Inc. ... conference call with,simultaneous webcast to discuss third quarter 2008 results on ... Mark N. K.,Bagnall, Executive Vice President and Chief Financial Officer, is ...
... and David,Simon, M.D. in Southern California helps people find relief from stress ... ... investments., SAN DIEGO, Oct. 30 As ... life savings,The Chopra Center for Wellbeing is teaching those impacted how to ...
Cached Medicine News:Health News:Phyhealth Announces Stock Buyback Program 2Health News:Phyhealth Announces Stock Buyback Program 3Health News:China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs 2Health News:Cardo Medical Announces FDA Clearance of the Align 360 Total Knee System 2Health News:Cardo Medical Announces FDA Clearance of the Align 360 Total Knee System 3Health News:Turbulent Times Turn The Chopra Center Into Mecca for Calm 2
... The Leica M520 OH3 ... the best optical performance available ... innovative and unique stand. The ... lightest, has the greatest range ...
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
PS Medical lumboperitoneal catheter systems are designed to divert CSF from the lumbar subarachnoid space to the peritoneal cavity, using simplified surgical techniques....
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Medicine Products: